Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
TXMD's Cash-to-Debt is ranked higher than
98% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. TXMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TXMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
0
No Debt
Equity-to-Asset 0.87
TXMD's Equity-to-Asset is ranked higher than
94% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. TXMD: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
TXMD' s Equity-to-Asset Range Over the Past 10 Years
Min: -294  Med: 0.9 Max: 0.98
Current: 0.87
-294
0.98
Interest Coverage No Debt
TXMD's Interest Coverage is ranked higher than
98% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. TXMD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TXMD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 55.89
Beneish M-Score: -2.39
WACC vs ROIC
10.31%
18772.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -489.34
TXMD's Operating Margin % is ranked lower than
92% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. TXMD: -489.34 )
Ranked among companies with meaningful Operating Margin % only.
TXMD' s Operating Margin % Range Over the Past 10 Years
Min: -14963.64  Med: -422.93 Max: -230.84
Current: -489.34
-14963.64
-230.84
Net Margin % -483.98
TXMD's Net Margin % is ranked lower than
92% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. TXMD: -483.98 )
Ranked among companies with meaningful Net Margin % only.
TXMD' s Net Margin % Range Over the Past 10 Years
Min: -15045.45  Med: -458.49 Max: -230.84
Current: -483.98
-15045.45
-230.84
ROE % -67.87
TXMD's ROE % is ranked lower than
87% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. TXMD: -67.87 )
Ranked among companies with meaningful ROE % only.
TXMD' s ROE % Range Over the Past 10 Years
Min: -878.1  Med: -106.71 Max: -59.77
Current: -67.87
-878.1
-59.77
ROA % -60.93
TXMD's ROA % is ranked lower than
89% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. TXMD: -60.93 )
Ranked among companies with meaningful ROA % only.
TXMD' s ROA % Range Over the Past 10 Years
Min: -979.74  Med: -136.19 Max: -53.85
Current: -60.93
-979.74
-53.85
ROC (Joel Greenblatt) % -17575.67
TXMD's ROC (Joel Greenblatt) % is ranked lower than
98% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. TXMD: -17575.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TXMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -87027.42  Med: -16379.15 Max: -650.11
Current: -17575.67
-87027.42
-650.11
3-Year Revenue Growth Rate -6.40
TXMD's 3-Year Revenue Growth Rate is ranked lower than
82% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. TXMD: -6.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TXMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.45 Max: 50
Current: -6.4
0
50
3-Year EBITDA Growth Rate -1.50
TXMD's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. TXMD: -1.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TXMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.55 Max: 186.2
Current: -1.5
0
186.2
3-Year EPS without NRI Growth Rate -0.90
TXMD's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. TXMD: -0.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TXMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -85.4 Max: 75.9
Current: -0.9
0
75.9
GuruFocus has detected 7 Warning Signs with TherapeuticsMD Inc TXMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TXMD's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

TXMD Guru Trades in Q2 2017

Steven Cohen 767,000 sh (+158.51%)
Ron Baron 850,000 sh (+126.79%)
» More
Q3 2017

TXMD Guru Trades in Q3 2017

Paul Tudor Jones 282,925 sh (New)
Ron Baron 920,000 sh (+8.24%)
Steven Cohen 282,600 sh (-63.16%)
» More
Q4 2017

TXMD Guru Trades in Q4 2017

First Eagle Investment 1,568,092 sh (New)
Ron Baron 1,000,000 sh (+8.70%)
Steven Cohen Sold Out
Paul Tudor Jones 44,931 sh (-84.12%)
» More
Q1 2018

TXMD Guru Trades in Q1 2018

Jim Simons 183,100 sh (New)
First Eagle Investment 1,747,336 sh (+11.43%)
Ron Baron 1,000,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TXMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-03-31 Add 11.43%$4.74 - $6.46 $ 7.0125%1,747,336
First Eagle Investment 2017-12-31 New Buy0.02%$4.36 - $6.8 $ 7.0126%1,568,092
Ron Baron 2017-12-31 Add 8.70%$4.36 - $6.8 $ 7.0126%1,000,000
Ron Baron 2017-09-30 Add 8.24%$4.6 - $6.91 $ 7.0121%920,000
Ron Baron 2017-06-30 Add 126.79%0.01%$3.84 - $8.09 $ 7.0139%850,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:SZSE:000739, SHSE:600422, BKK:MEGA, SZSE:300158, SHSE:600594, SHSE:600211, SZSE:002099, XPAR:VIRP, SHSE:600129, NAS:RTRX, DHA:RENATA, BOM:532300, TSE:4559, SZSE:300109, SZSE:002020, SHSE:900907, SHSE:600789, TSE:4534, SZSE:002433, NAS:ZGNX » details
Traded in other countries:29T.Germany,
Headquarter Location:USA
TherapeuticsMD Inc is a women's health care company focused on creating and commercializing products targeted exclusively for women. It is engaged in pre-commercialization activities for advanced hormone therapy pharmaceutical product.

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

Ratios

vs
industry
vs
history
PB Ratio 14.15
TXMD's PB Ratio is ranked lower than
86% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. TXMD: 14.15 )
Ranked among companies with meaningful PB Ratio only.
TXMD' s PB Ratio Range Over the Past 10 Years
Min: 0.35  Med: 9.03 Max: 29.97
Current: 14.15
0.35
29.97
PS Ratio 89.88
TXMD's PS Ratio is ranked lower than
93% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. TXMD: 89.88 )
Ranked among companies with meaningful PS Ratio only.
TXMD' s PS Ratio Range Over the Past 10 Years
Min: 0.05  Med: 52.84 Max: 2271.43
Current: 89.88
0.05
2271.43
EV-to-EBIT -17.41
TXMD's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. TXMD: -17.41 )
Ranked among companies with meaningful EV-to-EBIT only.
TXMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.6  Med: -10.8 Max: -0.1
Current: -17.41
-37.6
-0.1
EV-to-EBITDA -17.45
TXMD's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. TXMD: -17.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
TXMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.7  Med: -10.8 Max: -0.1
Current: -17.45
-37.7
-0.1
EV-to-Revenue 85.16
TXMD's EV-to-Revenue is ranked lower than
91% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. TXMD: 85.16 )
Ranked among companies with meaningful EV-to-Revenue only.
TXMD' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.1  Med: 54.3 Max: 2334.5
Current: 85.16
-0.1
2334.5
Current Ratio 7.61
TXMD's Current Ratio is ranked higher than
92% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. TXMD: 7.61 )
Ranked among companies with meaningful Current Ratio only.
TXMD' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 7.7 Max: 46.2
Current: 7.61
0.01
46.2
Quick Ratio 7.51
TXMD's Quick Ratio is ranked higher than
92% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. TXMD: 7.51 )
Ranked among companies with meaningful Quick Ratio only.
TXMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 7.48 Max: 39.8
Current: 7.51
0.01
39.8
Days Inventory 199.91
TXMD's Days Inventory is ranked lower than
79% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. TXMD: 199.91 )
Ranked among companies with meaningful Days Inventory only.
TXMD' s Days Inventory Range Over the Past 10 Years
Min: 69.65  Med: 190.05 Max: 298.25
Current: 199.91
69.65
298.25
Days Sales Outstanding 112.31
TXMD's Days Sales Outstanding is ranked lower than
64% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. TXMD: 112.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
TXMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.53  Med: 68.26 Max: 365
Current: 112.31
3.53
365
Days Payable 878.12
TXMD's Days Payable is ranked higher than
97% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. TXMD: 878.12 )
Ranked among companies with meaningful Days Payable only.
TXMD' s Days Payable Range Over the Past 10 Years
Min: 77.46  Med: 444.34 Max: 1943.84
Current: 878.12
77.46
1943.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.50
TXMD's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. TXMD: -11.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TXMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1303.7  Med: -10.1 Max: 0
Current: -11.5
-1303.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 16.69
TXMD's Price-to-Net-Cash is ranked higher than
61% of the 245 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.33 vs. TXMD: 16.69 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TXMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.11  Med: 8.13 Max: 150
Current: 16.69
1.11
150
Price-to-Net-Current-Asset-Value 14.60
TXMD's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 490 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.09 vs. TXMD: 14.60 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TXMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.64  Med: 11.9 Max: 83.33
Current: 14.6
0.64
83.33
Price-to-Tangible-Book 14.60
TXMD's Price-to-Tangible-Book is ranked lower than
81% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. TXMD: 14.60 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TXMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 7.23 Max: 132.09
Current: 14.6
0.55
132.09
Price-to-Median-PS-Value 1.70
TXMD's Price-to-Median-PS-Value is ranked lower than
67% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. TXMD: 1.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TXMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.93 Max: 35.23
Current: 1.7
0.01
35.23
Price-to-Peter-Lynch-Fair-Value 0.06
TXMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 188 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. TXMD: 0.06 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TXMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.43 Max: 6
Current: 0.06
0
6
Earnings Yield (Greenblatt) % -5.82
TXMD's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. TXMD: -5.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TXMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3824  Med: -9.25 Max: 35850
Current: -5.82
-3824
35850
Forward Rate of Return (Yacktman) % 137.40
TXMD's Forward Rate of Return (Yacktman) % is ranked higher than
100% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. TXMD: 137.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TXMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -621.2  Med: -51.2 Max: 137.4
Current: 137.4
-621.2
137.4

More Statistics

Revenue (TTM) (Mil) $16.57
EPS (TTM) $ -0.38
Beta1.23
Volatility52.08%
52-Week Range $4.34 - 7.66
Shares Outstanding (Mil)216.58

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 18 187 386
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.32 -0.10 0.22
EPS without NRI ($) -0.32 -0.10 0.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}